197 related articles for article (PubMed ID: 37844585)
1. Associations Between Immune-Related Venous Thromboembolism and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Li H; Li H; Tang L; Niu H; He L; Luo Q
Clin Appl Thromb Hemost; 2023; 29():10760296231206799. PubMed ID: 37844585
[TBL] [Abstract][Full Text] [Related]
2. Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis.
Cheung YM; Wang W; McGregor B; Hamnvik OR
Cancer Immunol Immunother; 2022 Aug; 71(8):1795-1812. PubMed ID: 35022907
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors.
Dutra B; Garcia-Rodriguez V; Garcia R; Szafron D; Abraham F; Khurana S; Lockhart J; Amin R; Wang Y; Thomas A
Am J Clin Oncol; 2023 Mar; 46(3):94-100. PubMed ID: 36735530
[TBL] [Abstract][Full Text] [Related]
5. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
6. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
7. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
[TBL] [Abstract][Full Text] [Related]
8. Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis.
Dall'Olio FG; Rizzo A; Mollica V; Massucci M; Maggio I; Massari F
Immunotherapy; 2021 Feb; 13(3):257-270. PubMed ID: 33225800
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies.
Amoroso V; Gallo F; Alberti A; Paloschi D; Ferrari Bravo W; Esposito A; Cosentini D; Grisanti S; Pedersini R; Petrelli F; Berruti A
ESMO Open; 2023 Apr; 8(2):100787. PubMed ID: 36842300
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis.
Du Y; Wu W; Chen M; Dong Z; Wang F
JAMA Dermatol; 2023 Oct; 159(10):1093-1101. PubMed ID: 37672255
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor.
le Sève JD; Guédon AF; Bordenave S; Agard C; Connault J; Pistorius MA; Quéreux G; Espitia O
Thromb Haemost; 2023 Nov; 123(11):1049-1056. PubMed ID: 37257835
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer.
Hayashi-Tanner Y; Polewski PJ; Gaddam M; Fisher NR; Kovacs AJ; Marinier DE
J Geriatr Oncol; 2022 Sep; 13(7):1011-1016. PubMed ID: 35637132
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann HJ
Cochrane Database Syst Rev; 2008 Apr; (2):CD006650. PubMed ID: 18425959
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
20. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment.
Wang Y; Yang M; Tao M; Liu P; Kong C; Li H; Chen Y; Yin X; Yan X
Int Immunopharmacol; 2021 Oct; 99():108031. PubMed ID: 34358857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
